Said Darwazah – Chief Executive Officer

Hello everyone.

Today we announced our results for the first half of 2026, and I am pleased to report a strong performance, ahead of last year and in line with our expectations. I’m also pleased to say that we have reiterated our full-year guidance for 2026. This is an important milestone for Hikma and demonstrates that we are delivering against the commitments we have made.

Branded, our MENA-based business, had an outstanding first half, growing revenue 15% and further strengthening its market-leading position. It is truly best-in-class and is an increasingly important driver of growth and profitability across the Group. 

As we promised, Hikma Rx also performed very well, with strong profit growth and significant margin expansion, well ahead of where we were in 2025. This performance was driven by our complex product offerings and our growing CMO business. 

In injectables, the actions we are taking are stabilising the business. We are deliberately increasing investment in R&D, our commercial platform and our manufacturing network in the US, Europe and MENA. 
These investments, along with the strengthening of our teams, will deliver an acceleration in absolute profit growth. 

We are increasingly agile. The more geographically aligned leadership structure we introduced this year is working well, bringing management closer to our markets and customers, and helping our teams act with greater speed and accountability. 
We have also taken clear, decisive action to increase R&D investment across the Group to accelerate the growth of our pipeline and focus the business on complex products with high barriers to entry.

With strong fundamentals, disciplined execution and clear strategic priorities, we remain confident in our full-year guidance, and I’m energised about delivering on it over the rest of the year.

I’m proud of the work we do at Hikma and the positive impact we have across the markets we operate in.  We are the largest pharma company in MENA and we are also one of the largest suppliers of US-made generic medicines in the US. In addition, we have recently become the fourth largest supplier of injectables in Europe.

We are focused on putting better health within reach for millions of people every day, and it is our talented colleagues who make this happen. I want to thank all of them for their excellent work in the first half of 2026. Thank you very much.